PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE ...

AB Science S.A. (the "Company" or "AB Science", Euronext – FR0010557264 – AB) announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the ...

AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) and preclinical animal model data have been accepted ...

Ab Science ((ABSCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Repayment of the balance of 0.2 million euros, quarterly between December 31, 2025 and June 30, 2026. The banks' agreement is conditional on the postponement by at least 12 months of the start of ...

i) Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral ...

(RTTNews) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April 2041. In Paris, AB ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease (i.e ...